CRESCENT BIOPHARMA, INC. (CBIO)
Score window: Apr. 15, 2025 to Apr. 14, 2026
| Date | Form | Sentiment | Urgency | Summary | Open |
|---|---|---|---|---|---|
| Jan. 13, 2026 | CORRESP | Neutral/Informational | Moderate | Crescent Biopharma, Inc. has submitted a request to the SEC for the acceleration of the effective date of their Registration Statement on Form S-1. They are seeking to have the re… | Read Filing EDGAR |
| Jan. 12, 2026 | UPLOAD | Neutral/Informational | Low | The SEC has communicated to Crescent Biopharma, Inc. that it will not review their registration statement filed on January 7, 2026. The letter emphasizes that the company and its … | Read Filing EDGAR |
| May. 13, 2025 | CORRESP | Neutral/Informational | Moderate | Crescent Biopharma, Inc. has submitted a request for the acceleration of the effective date of its Registration Statement on Form S-4. The company aims for the registration to bec… | Read Filing EDGAR |
| May. 12, 2025 | CORRESP | Neutral/Informational | Moderate | Crescent Biopharma, Inc. has submitted a response to the SEC regarding comments on their Amendment No. 2 to the Registration Statement on Form S-4. The correspondence addresses sp… | Read Filing EDGAR |
| May. 8, 2025 | UPLOAD | Concern from SEC | Moderate | The SEC has reviewed the amended registration statement for GlycoMimetics, Inc. and has issued comments requiring further clarification and amendments. Specifically, they request … | Read Filing EDGAR |
| Apr. 28, 2025 | CORRESP | Neutral/Informational | - | No summary returned. | Read Filing EDGAR |
| Apr. 22, 2025 | UPLOAD | Concern from SEC | High | The SEC has reviewed GlycoMimetics, Inc.'s amended registration statement and provided a series of comments requiring clarification and additional information. Key issues include … | Read Filing EDGAR |